Trials / Completed
CompletedNCT05318833
A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS7415 Tablets in Patients With Advanced Malignant Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open phase I clinical study of dose escalation and dose extension of HRS7415 in subjects with advanced malignant tumors. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS7415 tablets.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS7415 | Drug: HRS7415 |
Timeline
- Start date
- 2022-05-12
- Primary completion
- 2025-03-20
- Completion
- 2025-03-20
- First posted
- 2022-04-08
- Last updated
- 2026-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05318833. Inclusion in this directory is not an endorsement.